Munich Startup: As of April 1st, you took over the management of Biotechnology Innovation and Startup Center taken over. How did this come about?
Christian Gnam: Before taking over as managing director of the IZB, I held several roles with different focuses in the startup scene. During the last five years at the Insurtech Hub Munich (ITHM), my focus was on insurtech startups – including health insurance companies. This has led to strong connections to the healthcare sector and the digital health scene. During my previous role at Invest in Bavaria, I was able to support several biotech companies in establishing and expanding in Bavaria. This experience gave me insights into the industry and helped me build relevant contacts and networks. I was already fascinated by the biotech scene back then, and I am delighted to be able to support the companies and the industry even more actively through my work at the IZB.
Munich Startup: Hand on heart: How much respect do you have for the new task?
Christian Gnam: The management of the entire IZB Campus It definitely involves a very broad spectrum of tasks. From leasing and managing office and laboratory space to supporting biotech founders in their growth and managing the associated hotel and catering facilities. It's precisely this diversity that makes the job so exciting, and I look forward to being here on campus every day and tackling new challenges.
Promote exchange and establish contacts
Munich Startup: You were most recently Managing Director at Insurtech Hub Munich and previously led the investment team for startups, life sciences, energy and environmental technology, and chemicals at Invest in Bavaria. How can you apply this experience to your new position?
Christian Gnam: While every industry certainly presents its own challenges for startups, there are also issues that cross all industries. Founders, especially in the early stages, are often hyperfocused on developing their product. This quickly neglects something that is very important: networking and exchanging ideas with others, gaining new insights and establishing contacts. And this is precisely where I focused in my previous positions. With my teams, I facilitated important contacts, opened doors for startups, and thus accelerated their growth. This support can be applied to all industries.
Munich Startup: You are succeeding Dr. Peter Hanns Zobel, who held the management position for 28 years and is thus following in big footsteps: What do you want to keep – and what do you want to do differently?
Christian Gnam: First of all, I would like to emphasize that my predecessor built and set in motion an incredible amount over the past three decades. This magnificent campus, which I have taken over, is largely his achievement. At the same time, however, the demands and challenges facing companies are changing rapidly. AI, among other things, will have a major impact on biotech. I will address these and other developments and make adjustments accordingly.
Biotech location Munich
Munich Startup: Bavaria, and Munich in particular, is an important location for life science/biotechnology companies. How has the IZB contributed to this?
Christian Gnam: Before the IZB was founded in 1995, there was no place in Munich outside of the institutes and universities where young biotech companies could start and grow. The establishment of the IZB made this possible, and successful companies such as Morphosys and Micromet have emerged here. Since its founding, over 200 companies have found their home at the IZB. In addition to the purely technical infrastructure, a vibrant campus with neighboring institutes (Max Planck Institute and Ludwig Maximilian University of Munich) has gradually developed, where founders and researchers can network, inspire, and support each other. In this respect, the IZB has made a decisive contribution to making Munich an interesting and important location for the biotech industry.
Munich Startup: You'll also be a speaker at this year's Munich Startup Festival. In your opinion, what role does the Munich biotech cluster play in comparison to the rest of Europe?
Christian Gnam: In Europe, the Munich biotech cluster is one of the pioneers of the scene. The mix of universities, research institutes, global life science companies, international connections, the presence of local venture capital firms, and the strong industrial mix provides an excellent breeding ground for biotech start-ups. Other locations in Europe are also developing well, so we cannot rest on our laurels and must continuously develop the location and the framework conditions. I'm looking forward to this.
More public attention desirable
Munich Startup: What successes have startups based at the IZB achieved in recent years? Are there any particular challenges they will face in the future?
Christian Gnam: Despite the still tense situation on the venture capital market, many of our startups were able to raise substantial financing rounds in the two- to three-digit million range, including: Tubules, Insempra, Eisbach and Bind-X. This means that the biotech scene remains one of the strongest and most interesting target sectors for debt investments.
What always surprises me, however, is how little attention startups and the industry in general receive in Germany—measured both in terms of their funding rounds and their significant technological developments. I would like to see more interest and greater public support in this area.
Promoting international networking
Munich Startup: What plans and visions do you have for the IZB in the coming years?
Christian Gnam: The range of tasks at the IZB is as broad as the number of topics I want to tackle in the coming years. One of these is AI, which will also play an increasingly important role in the biotech industry. While most of our companies are already using AI for their research, we are only at the beginning of its potential. Therefore, my goal is to significantly expand the expertise on the IZB campus in terms of user knowledge (preferably across industries) and infrastructure.
Major technological innovations—whether in IT or biotech research—always occur on a global scale. It is therefore important to me to intensify international networking with other leading biotech research and startup locations to promote knowledge exchange. This can generate more investment activity and collaboration opportunities on both sides, benefiting the industry as a whole. At the same time, knowledge exchange can also be further expanded locally. In Munich and Bavaria, we have many great technology initiatives and research expertise that parts of our community are not yet aware of and from which they could benefit. For these and other measures, I will also work closely with our partners, such as the cluster organization BioM and neighboring top research institutes.
